Kiromic BioPharma, Inc. (NASDAQ:KRBP) to Post Q1 2023 Earnings of ($0.43) Per Share, Diamond Equity Forecasts

Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Rating) – Equities research analysts at Diamond Equity issued their Q1 2023 EPS estimates for Kiromic BioPharma in a research note issued to investors on Thursday, May 19th. Diamond Equity analyst H. Diamond forecasts that the company will post earnings of ($0.43) per share for the quarter. Diamond Equity also issued estimates for Kiromic BioPharma’s Q2 2023 earnings at ($0.45) EPS, Q3 2023 earnings at ($0.47) EPS, Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($1.85) EPS and FY2024 earnings at ($1.99) EPS.

Kiromic BioPharma (NASDAQ:KRBP – Get Rating) last posted its quarterly earnings data on Friday, March 11th. The company reported ($0.40) earnings per share (EPS) for the quarter.

NASDAQ KRBP opened at $0.31 on Monday. The stock’s 50-day moving average price is $0.69 and its two-hundred day moving average price is $1.26. The company has a market cap of $4.78 million, a PE ratio of -0.38 and a beta of 0.61. Kiromic BioPharma has a 1 year low of $0.29 and a 1 year high of $11.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of KRBP. 1492 Capital Management LLC grew its stake in Kiromic BioPharma by 21.3% during the 3rd quarter. 1492 Capital Management LLC now owns 434,408 shares of the company’s stock valued at $1,334,000 after acquiring an additional 76,402 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Kiromic BioPharma during the 1st quarter valued at about $48,000. LPL Financial LLC purchased a new position in Kiromic BioPharma during the 3rd quarter valued at about $162,000. Geode Capital Management LLC purchased a new position in Kiromic BioPharma during the 3rd quarter valued at about $158,000. Finally, Warberg Asset Management LLC grew its stake in Kiromic BioPharma by 118.4% during the 1st quarter. Warberg Asset Management LLC now owns 73,847 shares of the company’s stock valued at $63,000 after acquiring an additional 40,032 shares in the last quarter. Hedge funds and other institutional investors own 16.03% of the company’s stock.

Kiromic BioPharma Company Profile (Get Rating)

Kiromic BioPharma, Inc, a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy.

Featured Stories